Skip to content

Design of an Integrative Algorithm for Staging Tuberculosis

Design of an Integrative Algorithm for Staging Tuberculosis to Improve Clinical Management.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03691883
Acronym
STAGE-TB
Enrollment
200
Registered
2018-10-02
Start date
2018-04-19
Completion date
2026-12-31
Last updated
2024-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Keywords

tuberculosis, infectious diseases

Brief summary

Tuberculosis is a chronic infectious disease that affects 10 million people, 300 in the city of Barcelona, every year. With serious consequences at public health level, it is associated with other diseases, and generated and influenced by many social and psychological factors. This study aims to stage tuberculosis disease by an integrative approach.

Detailed description

Tuberculosis is a chronic infectious disease that affects 10 million people, there are 300 new cases 300 in the city of Barcelona, every year. Tuberculosis has serious consequences at public health level. It is associated with other diseases, and generated and influenced by many social and psychological factors. This study aims to stage tuberculosis disease by a novel integrative approach.

Interventions

None listed

Sponsors

Hospital Universitari Vall d'Hebron (Drassanes)
CollaboratorUNKNOWN
Servicios Clínicos de Barcelona
CollaboratorUNKNOWN
Germans Trias i Pujol Hospital
CollaboratorOTHER
Hospital Sant Joan de Deu
CollaboratorOTHER
Hospital del Mar
CollaboratorOTHER
Fundació Institut Germans Trias i Pujol
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* TB diagnosis (all forms), microbiologically confirmed (by AFB+, GenXpert+ or Culture+) * Clinical management of the patients being done at Servicios Clínicos, Hospital Universitari Vall d'Hebron-Drassanes or Hospital Universitari Germans Trias i Pujol.

Exclusion criteria

* Not consenting to data/samples donation

Design outcomes

Primary

MeasureTime frameDescription
Clinical changestimepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)Changes in clinical status
Microbiological changestimepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)Changes in microbiological cultures

Secondary

MeasureTime frameDescription
Changes in SGRQ scoretimepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)Changes in Health Quality of Life measures along time assessed by using the Saint George's Respiratory Questionnaire (SGRQ, numeric score). It measures 3 subscales (symptoms/activity/impacts) and The Total score is calculated by summing all positive responses in the questionnaire and expressing the result as a percentage of the total weight for the questionnaire. Higher values represent a worse outcome.
Changes in Biomarkers valuestimepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)Changes in the biomarkers along time assessed by using analyzing parameters in blood and urine samples (by ELISA and LUMINEX)
Changes in Health Quality of Life measures along time using BCN-Q questionnairetimepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)Changes in Health Quality of Life measures along time using BCN-Q questionnaire (descriptive questionnaire).
Changes in Kessler-10 scoretimepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)Changes in Health Quality of Life measures along time assessed by using the questionnaire Kessler-10 (K10, numeric score). Higher values represent a worse outcome.
Radiological Score Valuetimepoints 0 (at inclusion), at month 2 and month 6 (and month 12 if MDR/XDR)Changes in the BCN-SA Radiological Score Value. This Score assesses the sum of acute and chronic findings in the chest X-ray. Per each finding, a maximum score of 8 is recorded. The total score value is calculated by adding all the individual findings score values. Higher values of total score represent a worse outcome.

Countries

Spain

Contacts

Primary ContactCris Vilaplana, MD, PhD
cvilaplana@gmail.com934978677
Backup ContactLaura Villegas
secretary.ute@gmail.com+34934978681

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026